Research programme: dual tumour necrosis factor/matrix metalloproteinase inhibitors - Roche

Drug Profile

Research programme: dual tumour necrosis factor/matrix metalloproteinase inhibitors - Roche

Alternative Names: Dual TNF/MMP inhibitors research programme - Roche; Dual tumour necrosis factor/matrix metalloproteinase inhibitors research programme - Roche; Research programme: dual TNF/MMP inhibitors - Roche

Latest Information Update: 12 Apr 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche Palo Alto LLC
  • Class
  • Mechanism of Action Matrix metalloproteinase inhibitors; Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 12 Apr 2007 No development reported - Preclinical for Rheumatoid arthritis in USA (PO)
  • 07 Sep 2004 Preclinical trials in Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top